Zacks Investment Research cut shares of Nivalis Therapeutics Inc. (NASDAQ:NVLS) from a hold rating to a sell rating in a research report released on Wednesday.

According to Zacks, “Nivalis Therapeutics, Inc. is a pharmaceutical company. The company is engaged in discovery, development and commercialization of molecule therapeutics for cystic fibrosis. Nivalis Therapeutics, Inc. is headquartered in Boulder, Colorado. “

Several other research firms also recently weighed in on NVLS. HC Wainwright restated a buy rating on shares of Nivalis Therapeutics in a research report on Monday, August 8th. Raymond James Financial Inc. initiated coverage on Nivalis Therapeutics in a research report on Tuesday, September 13th. They issued an outperform rating and a $20.00 target price on the stock. Cowen and Company restated a buy rating on shares of Nivalis Therapeutics in a research report on Monday, August 1st. Finally, Piper Jaffray Cos. restated a buy rating and issued a $16.00 target price on shares of Nivalis Therapeutics in a research report on Tuesday, August 30th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $13.75.

Nivalis Therapeutics (NASDAQ:NVLS) opened at 7.46 on Wednesday. The firm has a 50-day moving average price of $7.52 and a 200 day moving average price of $5.36. Nivalis Therapeutics has a 12 month low of $3.68 and a 12 month high of $9.45. The company’s market cap is $115.65 million.

Nivalis Therapeutics (NASDAQ:NVLS) last released its earnings results on Monday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.03. Equities research analysts predict that Nivalis Therapeutics will post ($2.29) EPS for the current year.

In other Nivalis Therapeutics news, EVP David Malcom Rodman sold 5,820 shares of Nivalis Therapeutics stock in a transaction on Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the sale, the executive vice president now owns 18,056 shares in the company, valued at $143,725.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.00% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the stock. BVF Inc. IL increased its stake in Nivalis Therapeutics by 29.4% in the first quarter. BVF Inc. IL now owns 1,546,743 shares of the company’s stock worth $6,450,000 after buying an additional 351,730 shares in the last quarter. State Street Corp increased its stake in Nivalis Therapeutics by 4.5% in the first quarter. State Street Corp now owns 44,495 shares of the company’s stock worth $186,000 after buying an additional 1,900 shares in the last quarter. Opaleye Management Inc. acquired a new stake in Nivalis Therapeutics during the first quarter worth approximately $417,000. Sabby Management LLC increased its stake in Nivalis Therapeutics by 31.5% in the first quarter. Sabby Management LLC now owns 662,058 shares of the company’s stock worth $2,761,000 after buying an additional 158,463 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in Nivalis Therapeutics during the second quarter worth approximately $105,000. Institutional investors own 83.12% of the company’s stock.

About Nivalis Therapeutics

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Stock Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related stocks with our FREE daily email newsletter.